之江生物(688317.SH)高開逾15% 猴痘病毒核酸測定試劑盒已有國內外訂單
格隆匯5月23日丨之江生物(688317.SH)跳空高開15.16%報47.56元,市值92.6億元。之江生物稱,公司猴痘病毒核酸檢測試劑盒(熒光PCR法)可準確鑑別猴痘病毒,已經獲得歐盟CE認證,已有國內外訂單,國內僅供於疾控及科研用途。世衞組織稱,全球已有12個國家和地區報吿猴痘病例,猴痘是由於猴痘病毒感染造成的疾病,猴痘病毒是天花病毒的近親,是一種人畜共患病毒。世衞組織稱,現有信息顯示,與有症狀的病例發生密切身體接觸的人羣中正在發生人際傳播。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.